Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
11th December 2022
Portfolio
This post references, or is about Harpoon. Find out more by clicking below
11th December 2022
Portfolio
This post references, or is about Harpoon. Find out more by clicking below
Print Article
Email Article
Save Article
